100% Bacteria free eggs for use in production of human and animal vaccines

Project description

Eliminating bacterial contamination through eggs for vaccine development and production

In times when immunisation has become a universal demand, any practice that transforms vaccine production, facilitates the work of health service providers and enables a rapid response to global pandemics is extremely valuable. The EU-funded OvaVax project aims to become the go-to supplier of the world's first superior-quality germ-free eggs to the vaccine industry globally by 2021. The project is led by an innovation-based biotechnology company that utilises disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. The new process they are proposing will address the increasing demand for safe, fast and cost-effective solutions in vaccine manufacturing.

Fields of science

• natural sciences › biological sciences › microbiology › bacteriology
• medical and health sciences › basic medicine › immunology › immunisation
• social sciences › economics and business › business and management › entrepreneurship
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-SMEInst-2018-2020-2
See other projects for this call

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

OVAGEN GROUP LIMITED

Address

Carrentrila
F26PC79 Ballina
Ireland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

EU contribution

€ 2 356 812,50